MORRISVILLE, N.C., August 1, 2022 – Myocardial Solutions, Inc. (MSI) released a new software version in the United States much like version 5.2.4 for the European Market.
The updated software features semi-auto contouring of cardiac imaging. “MSI continues to incorporate AI for faster and more comprehensive assessment of the health of the heart. With semi-auto contouring, a full picture of cardiac global and regional function is produced with minimal user interaction. It is an assistant to the user for speed while maintaining the high accuracy of MyoStrain reports,” commented Dr. Nael Osman, Chief Scientific Officer, Myocardial Solutions, Inc. Other features addressed certain customer requests representing continual improvement.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.
808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | myocardialsolutions.com | ph: +1.919.677.8100
© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM
Score are among the trademarks of Myocardial Solutions.